Breaking News Instant updates and real-time market news.

RXDX

Prometheus

$117.34 /

+21.41 (+22.32%)

20:04
12/08/22
12/08
20:04
12/08/22
20:04

Prometheus 4.55M share Secondary priced at $110.00

The deal size was increased to $500M from $250M and priced below last closing price of $117.64. Goldman Sachs, SVB Securities, Jefferies and Guggenheim are acting as joint book running managers for the offering.

  • 09

    Dec

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Takeda Pharmaceutical: FDA approves sBLA for expanded use of TAKHZYRO » 18:51
02/03/23
02/03
18:51
02/03/23
18:51
TAK

Takeda Pharmaceutical

$15.98 /

+0.255 (+1.62%)

Takeda announced that the…

Takeda announced that the U.S. FDA has approved the supplemental Biologics License Application for the expanded use of TAKHZYRO for prophylaxis to prevent attacks of hereditary angioedema in pediatric patients 2 to less than12 years of age. Prior to this approval, the only approved routine prophylaxis treatment options for children 6 to less than12 years of age required dosing every three to four days, and children with HAE 2 to less than 6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group. The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to less than 6 years of age and every two weeks in patients 6 to less than 12 years of age.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$15.98 /

+0.255 (+1.62%)

TAK Takeda Pharmaceutical
$15.98 /

+0.255 (+1.62%)

01/03/23 Wells Fargo
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
12/13/22 Piper Sandler
Takeda deal has positive read through for Ventyx, says Piper
11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
TAK Takeda Pharmaceutical
$15.98 /

+0.255 (+1.62%)

Hot Stocks
LGI Homes announced it closed 331 homes in January » 18:29
02/03/23
02/03
18:29
02/03/23
18:29
LGIH

LGI Homes

$121.77 /

-2.525 (-2.03%)

As of January 31, the…

As of January 31, the company had 97 active selling communities.

ShowHide Related Items >><<
LGIH LGI Homes
$121.77 /

-2.525 (-2.03%)

LGIH LGI Homes
$121.77 /

-2.525 (-2.03%)

11/22/22 JPMorgan
LGI Homes price target raised to $84 from $73 at JPMorgan
10/10/22 Wedbush
LGI Homes price target lowered to $84 from $94 at Wedbush
08/03/22 JMP Securities
LGI Homes price target lowered to $140 from $175 at JMP Securities
07/12/22 JPMorgan
LGI Homes price target lowered to $77 from $85 at JPMorgan
LGIH LGI Homes
$121.77 /

-2.525 (-2.03%)

Hot Stocks
Atento announces successful capital raise » 18:16
02/03/23
02/03
18:16
02/03/23
18:16
ATTO

Atento

$4.40 /

-1 (-18.52%)

Atento confirms that it…

Atento confirms that it has secured its previously announced financing program. The additional capital raised will further strengthen Atento's balance sheet and liquidity position as management focuses on transforming the business. The fourth quarter has continued the positive trend by generating strong EBITDA margin growth, delivering the cash balance to close at $84M on December 31, 2022.

ShowHide Related Items >><<
ATTO Atento
$4.40 /

-1 (-18.52%)

ATTO Atento
$4.40 /

-1 (-18.52%)

08/15/22 Barrington
Atento price target lowered to $15 from $32 at Barrington
ATTO Atento
$4.40 /

-1 (-18.52%)

Hot Stocks
Sony delays 'The Last of Us Part I' PC port to March 28 » 18:07
02/03/23
02/03
18:07
02/03/23
18:07
SONY

Sony

$93.12 /

-0.72 (-0.77%)

Sony's Naughty Dog…

Sony's Naughty Dog has delated the PC port of 2022 video game "The Last of Us Part I" to March 28 from March 3. The game, which is a remake of the 2013 game of the same name, originally launched in 2022 for PlayStation 5. Reference Link

ShowHide Related Items >><<
SONY Sony
$93.12 /

-0.72 (-0.77%)

SONY Sony
$93.12 /

-0.72 (-0.77%)

02/03/23 Cowen
Sony price target raised to $118 from $102 at Cowen
11/02/22 Cowen
Sony price target lowered to $102 from $144 at Cowen
10/13/22 Oppenheimer
Oppenheimer sees more difficulty for Microsoft/Activision to win CMA approval
09/07/22 Goldman Sachs
Sony resumed with a Neutral at Goldman Sachs
SONY Sony
$93.12 /

-0.72 (-0.77%)

SONY Sony
$93.12 /

-0.72 (-0.77%)

SONY Sony
$93.12 /

-0.72 (-0.77%)

SONY Sony
$93.12 /

-0.72 (-0.77%)

Periodicals
Elon Musk prevails in shareholder lawsuit over 2018 tweet, WSJ says » 18:03
02/03/23
02/03
18:03
02/03/23
18:03
TSLA

Tesla

$189.96 /

+1.64 (+0.87%)

A jury rejected…

A jury rejected shareholder claims that Elon Musk violated federal securities law when he tweeted in 2018 about potentially taking Tesla private, The Wall Street Journal's Rebecca Elliott reports. The nine-person jury said the investors who brought the class-action case failed to prove that Musk hurt them by tweeting about a possible deal. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$189.96 /

+1.64 (+0.87%)

TSLA Tesla
$189.96 /

+1.64 (+0.87%)

01/30/23 Bernstein
Bernstein sees orders as 'most critical' to Tesla stock
01/30/23 Berenberg
Tesla upgraded to Buy from Hold at Berenberg
01/26/23 Morgan Stanley
Tesla FY23 earnings could bottom near $3 per share, says Morgan Stanley
01/26/23 Wedbush
Tesla price target raised to $200 from $175 at Wedbush
TSLA Tesla
$189.96 /

+1.64 (+0.87%)

TSLA Tesla
$189.96 /

+1.64 (+0.87%)

TSLA Tesla
$189.96 /

+1.64 (+0.87%)

TSLA Tesla
$189.96 /

+1.64 (+0.87%)

Hot Stocks
ArrowMark Financial Corp. reports estimated NAV $20.79 as of December 31 » 17:46
02/03/23
02/03
17:46
02/03/23
17:46
BANX

ArrowMark Financial Corp.

$18.62 /

+0.32 (+1.75%)

This NAV reflects the…

This NAV reflects the regular fourth quarter dividend of 39c per share plus the special dividend of 10c per share.

ShowHide Related Items >><<
BANX ArrowMark Financial Corp.
$18.62 /

+0.32 (+1.75%)

Hot Stocks
BMW invests EUR800M in Mexican production site for electric vehicles » 17:31
02/03/23
02/03
17:31
02/03/23
17:31
BMWYY

BMW

$34.97 /

-0.54 (-1.52%)

The BMW Group is…

The BMW Group is investing EUR800M in its Mexican production site in San Luis Potosi for the integration of fully electric models of NEUE KLASSE and construction of local high-voltage battery assembly. The company said that the move will lead to 1,000 new jobs at the San Luis Potosi factory and could mean that achieving 50% share of the company's worldwide sales of fully electric vehicles earlier than 2030. "We are systematically gearing our production network towards electromobility. In Mexico, we are investing 800 million euros in our plant and creating around 1,000 new jobs," explained Milan Nedeljkovi, member of the Board of Management of BMW AG responsible for Production, in San Luis Potosi at an event attended by Mexican President Andres Manuel Lopez Obrador and Governor of San Luis Potosi Ricardo Gallardo Cardona.

ShowHide Related Items >><<
BMWYY BMW
$34.97 /

-0.54 (-1.52%)

BMWYY BMW
$34.97 /

-0.54 (-1.52%)

02/02/23 Kepler Cheuvreux
BMW downgraded to Reduce from Hold at Kepler Cheuvreux
01/30/23 Berenberg
BMW downgraded to Hold from Buy at Berenberg
01/25/23 Morgan Stanley
BMW price target lowered to EUR 85 from EUR 90 at Morgan Stanley
01/13/23 JPMorgan
BMW price target raised to EUR 95 from EUR 90 at JPMorgan
BMWYY BMW
$34.97 /

-0.54 (-1.52%)

BMWYY BMW
$34.97 /

-0.54 (-1.52%)

Syndicate
Getaround files to sell 127.42M shares of common stock for holders  17:24
02/03/23
02/03
17:24
02/03/23
17:24
GETR

Getaround

/

+

 
ShowHide Related Items >><<
GETR Getaround
/

+

GETR Getaround
/

+

01/13/23 Wedbush
Getaround initiated with an Outperform at Wedbush
12/29/22 Piper Sandler
Getaround initiated with an Overweight at Piper Sandler
GETR Getaround
/

+

Syndicate
Kiora Pharmaceuticals files to sell 1.05M shares of common stock for holders  17:23
02/03/23
02/03
17:23
02/03/23
17:23
KPRX

Kiora Pharmaceuticals

$3.52 /

+ (+0.00%)

 
ShowHide Related Items >><<
KPRX Kiora Pharmaceuticals
$3.52 /

+ (+0.00%)

KPRX Kiora Pharmaceuticals
$3.52 /

+ (+0.00%)

01/03/23 Ladenburg
Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg
08/25/22 Ladenburg
Ladenburg starts ophthalmic-focused Kiora with a Buy
08/25/22 Ladenburg
Kiora Pharmaceuticals initiated with a Buy at Ladenburg
08/15/22 Maxim
Kiora Pharmaceuticals downgraded to Hold from Buy at Maxim
Syndicate
Durect announces $10M registered direct offering of common stock, warrants » 17:21
02/03/23
02/03
17:21
02/03/23
17:21
DRRX

Durect

$6.44 /

+0.125 (+1.98%)

Durect announced that it…

Durect announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying warrants to purchase up to 2,000,000 shares of common stock in a registered direct offering. The shares of common stock and accompanying warrants are being sold at a combined purchase price of $5.00 per share and accompanying warrant, and the pre-funded warrants are being sold at a combined purchase price of $4.99999 per pre-funded warrant and accompanying warrant. All of the shares of common stock, pre-funded warrants and accompanying warrants to be sold in the Offering will be sold by Durect. The pre-funded warrants have an exercise price of $0.00001 per share and the accompanying warrants will have an exercise price of $5.00 per share. The pre-funded warrants and the accompanying warrants will be immediately exercisable. The pre-funded warrants do not expire and the accompanying warrants will expire five years from the date of issuance. The closing of the Offering is expected to occur on or about February 8, 2023, subject to customary closing conditions. The gross proceeds from the Offering are expected to be approximately $10M, before deducting fees to the placement agents and other estimated offering expenses payable by Durect. Durect intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. Cantor Fitzgerald & Co. and Oppenheimer & Co. are acting as lead placement agents for the Offering.

ShowHide Related Items >><<
DRRX Durect
$6.44 /

+0.125 (+1.98%)

DRRX Durect
$6.44 /

+0.125 (+1.98%)

12/07/22 Oppenheimer
Durect price target raised to $32 from $6 at Oppenheimer
12/06/22 H.C. Wainwright
Durect target adjusted to $35 for stock split at H.C. Wainwright
03/08/22 H.C. Wainwright
H.C. Wainwright keeps $6 target on Durect after Q4 results
03/04/22 H.C. Wainwright
Durect CFO exit does not impact positive thesis, says H.C. Wainwright
DRRX Durect
$6.44 /

+0.125 (+1.98%)

Syndicate
IO Biotech files $250M mixed securities shelf  17:21
02/03/23
02/03
17:21
02/03/23
17:21
IOBT

IO Biotech

$2.71 /

-0.035 (-1.28%)

 
ShowHide Related Items >><<
IOBT IO Biotech
$2.71 /

-0.035 (-1.28%)

IOBT IO Biotech
$2.71 /

-0.035 (-1.28%)

11/21/22 H.C. Wainwright
IO Biotech initiated with a Buy at H.C. Wainwright
IOBT IO Biotech
$2.71 /

-0.035 (-1.28%)

Conference/Events
Activision Blizzard management to meet virtually with Benchmark » 17:08
02/03/23
02/03
17:08
02/03/23
17:08
ATVI

Activision Blizzard

$75.23 /

-1.92 (-2.49%)

Virtual Meeting to be…

Virtual Meeting to be held with SVP Investor Relations Hickey on February 9 at 12 pm hosted by Benchmark.

ShowHide Related Items >><<
ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

01/27/23 Wedbush
Activision Blizzard assumed with an Outperform at Wedbush
12/22/22 Needham
Netflix 2023 estimates cut at Needham
12/06/22 Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

ATVI Activision Blizzard
$75.23 /

-1.92 (-2.49%)

Syndicate
Lilium files to sell 3.1M Class A ordinary shares for holders  17:08
02/03/23
02/03
17:08
02/03/23
17:08
LILM

Lilium

$1.37 /

+0.045 (+3.40%)

 
ShowHide Related Items >><<
LILM Lilium
$1.37 /

+0.045 (+3.40%)

LILM Lilium
$1.37 /

+0.045 (+3.40%)

12/07/22 Piper Sandler
Lilium price target lowered to $7 from $9 at Piper Sandler
12/07/22 Barclays
Lilium downgraded to Underweight from Equal Weight at Barclays
11/15/22 Barclays
Lilium price target lowered to $2 from $5 at Barclays
08/30/22 Piper Sandler
Lilium price target lowered to $10 from $15 at Piper Sandler
LILM Lilium
$1.37 /

+0.045 (+3.40%)

Syndicate
Hempacco files to sell 4.73M shares of common stock » 17:06
02/03/23
02/03
17:06
02/03/23
17:06
HPCO

Hempacco

$1.05 /

-0.11 (-9.48%)

The company currently…

The company currently estimates that the public offering price will be $1.11 per share.

ShowHide Related Items >><<
HPCO Hempacco
$1.05 /

-0.11 (-9.48%)

  • 30
    Aug
HPCO Hempacco
$1.05 /

-0.11 (-9.48%)

Hot Stocks
Forest Road Acquisition Corp. II, HyperloopTT terminate merger agreement » 17:02
02/03/23
02/03
17:02
02/03/23
17:02
FRXB

Forest Road Acquisition Corp. II

$10.13 /

+0.03 (+0.30%)

Hyperloop Transportation…

Hyperloop Transportation Technologies and Forest Road Acquisition Corp. II have mutually agreed to terminate their previously announced business combination agreement. Considering the significant time to close the business combination, coupled with prevailing market conditions, both parties decided that terminating the agreement is in the best interest of their respective shareholders and employees.

Syndicate
SAB Biotherapeutics files to sell 7.36M shares of common stock for holders  17:02
02/03/23
02/03
17:02
02/03/23
17:02
SABS

SAB Biotherapeutics

/

+

 
ShowHide Related Items >><<
SABS SAB Biotherapeutics
/

+

SABS SAB Biotherapeutics
/

+

11/29/22 H.C. Wainwright
SAB Biotherapeutics initiated with a Buy at H.C. Wainwright
08/11/22 Chardan
SAB Biotherapeutics price target lowered to $3 from $7 at Chardan
08/11/22 Baird
SAB Biotherapeutics price target lowered to $4 from $8 at Baird
05/13/22 Chardan
SAB Biotherapeutics price target lowered to $7 from $10 at Chardan
SABS SAB Biotherapeutics
/

+

Hot Stocks
GAP Airports reports preliminary January passenger traffic up 33.1% » 17:01
02/03/23
02/03
17:01
02/03/23
17:01
PAC

GAP Airports

$180.51 /

+0.375 (+0.21%)

For January 2023, the…

For January 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 30.0%, compared to the same period of 2022. Puerto Vallarta, Los Cabos, Guadalajara, and Tijuana presented an increase in passenger traffic of 46.5%, 39.2%, 31.7%, and 20.1% respectively, compared to January 2022. On the other hand, Montego Bay increase by 67.6% and Kingston 59.6%, compared to 2022.

ShowHide Related Items >><<
PAC GAP Airports
$180.51 /

+0.375 (+0.21%)

PAC GAP Airports
$180.51 /

+0.375 (+0.21%)

10/20/22 Grupo Santander
GAP Airports downgraded to Underperform from Neutral at Grupo Santander
08/25/22 HSBC
GAP Airports upgraded to Buy from Hold at HSBC
08/08/22 JPMorgan
GAP Airports upgraded to Neutral from Underweight at JPMorgan
05/03/22 JPMorgan
GAP Airports downgraded to Underweight from Neutral at JPMorgan
Conference/Events
Columbia Sportswear management to meet virtually with Seaport Global » 17:00
02/03/23
02/03
17:00
02/03/23
17:00
COLM

Columbia Sportswear

$93.60 /

-2.49 (-2.59%)

Virtual Meeting to be…

Virtual Meeting to be held on February 9 hosted by Seaport Global.

ShowHide Related Items >><<
COLM Columbia Sportswear
$93.60 /

-2.49 (-2.59%)

COLM Columbia Sportswear
$93.60 /

-2.49 (-2.59%)

02/03/23 Baird
Columbia Sportswear price target raised to $97 from $92 at Baird
01/23/23 UBS
Columbia Sportswear price target raised to $92 from $90 at UBS
09/29/22 Citi
Citi cuts VF target, says reduced outlook still 'somewhat aggressive'
09/27/22 Cowen
Columbia Sportswear price target raised to $86 from $85 at Cowen
COLM Columbia Sportswear
$93.60 /

-2.49 (-2.59%)

COLM Columbia Sportswear
$93.60 /

-2.49 (-2.59%)

Conference/Events
Bread Financial management to meet virtually with Seaport Global » 16:59
02/03/23
02/03
16:59
02/03/23
16:59
BFH

Bread Financial

$42.78 /

-1.22 (-2.77%)

Virtual Meeting to be…

Virtual Meeting to be held on February 7 hosted by Seaport Global.

ShowHide Related Items >><<
BFH Bread Financial
$42.78 /

-1.22 (-2.77%)

BFH Bread Financial
$42.78 /

-1.22 (-2.77%)

02/01/23 BTIG
CFPB credit card late fee proposal 'more onerous than expected,' says BTIG
01/26/23 Stephens
Stephens remains buyer of Bread Financial on weakness
01/05/23 Stephens
Stephens raises 'most conservative' card company Bread Financial to Overweight
01/05/23 Stephens
Bread Financial upgraded to Overweight from Equal Weight at Stephens
BFH Bread Financial
$42.78 /

-1.22 (-2.77%)

BFH Bread Financial
$42.78 /

-1.22 (-2.77%)

Syndicate
Comera Life Sciences files to sell 7.22M shares of common stock for holders  16:57
02/03/23
02/03
16:57
02/03/23
16:57
CMRA

Comera Life Sciences

$1.34 /

+0.01 (+0.75%)

 
ShowHide Related Items >><<
CMRA Comera Life Sciences
$1.34 /

+0.01 (+0.75%)

CMRA Comera Life Sciences
$1.34 /

+0.01 (+0.75%)

Syndicate
Travelzoo files to sell 3.41M shares of common stock for holders  16:54
02/03/23
02/03
16:54
02/03/23
16:54
TZOO

Travelzoo

$4.83 /

-0.37 (-7.12%)

 
ShowHide Related Items >><<
TZOO Travelzoo
$4.83 /

-0.37 (-7.12%)

TZOO Travelzoo
$4.83 /

-0.37 (-7.12%)

11/28/22 Barrington
Travelzoo downgraded to Market Perform from Outperform at Barrington
08/08/22 Ascendiant
Travelzoo upgraded to Buy from Hold at Ascendiant
07/29/22 Barrington
Travelzoo price target lowered to $10 from $12 at Barrington
03/18/22 Ascendiant
Travelzoo downgraded to Hold from Buy at Ascendiant
TZOO Travelzoo
$4.83 /

-0.37 (-7.12%)

TZOO Travelzoo
$4.83 /

-0.37 (-7.12%)

Hot Stocks
KVH Industries enters support agreement with Black Diamond Capital » 16:49
02/03/23
02/03
16:49
02/03/23
16:49
KVHI

KVH Industries

$10.01 /

+ (+0.00%)

KVH Industries announced…

KVH Industries announced that it has entered into a support agreement with Black Diamond Capital Management, L.L.C. and certain of its affiliates. Pursuant to the Agreement, the company has committed to nominate and support Black Diamond Managing Principal Stephen Deckoff as an independent Class III director at the company's 2023 Annual Meeting of Stockholders, subject to certain conditions. Deckoff will begin serving as a non-voting observer of the company's Board of Directors. Additionally, the company has granted Black Diamond a waiver under the company's stockholder rights plan allowing Black Diamond to acquire up to 25% of the company's outstanding common stock. The company will accept the resignation of one of its incumbent directors, which resignation will become effective at the 2023 Annual Meeting. Following the election of Deckoff at the 2023 Annual Meeting, the KVH Board will continue to have seven directors.

ShowHide Related Items >><<
KVHI KVH Industries
$10.01 /

+ (+0.00%)

KVHI KVH Industries
$10.01 /

+ (+0.00%)

12/08/22 Raymond James
KVH Industries downgraded to Market Perform from Strong Buy at Raymond James
KVHI KVH Industries
$10.01 /

+ (+0.00%)

General news
Treasury Market Summary: » 16:40
02/03/23
02/03
16:40
02/03/23
16:40
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: a blowout January jobs report crushed a Treasury market which had geared itself up for a an end to Fed rate hikes next month and rate cuts later in the year. Broadbased strength in report and a solid pop in the iSM services index added to signs of a still tight labor market and a resilient economy, while contradicting expectations of a recession. Nearly every aspect of employment release were stronger than expected, not just the 517k pop in payrolls and the dive in the unemployment rate to 3.4%. Treasury yields reacted immediately, knee-jerking higher and extending up through the day. The 2-year jumped 22 bps higher to hit 4.313%, the highest since January 4. The refunding issues cheapened measurably with the wi 3-year 20 bps cheaper at 3.95%, the wi 10-year 16.5 bps higher to 3.54%, and the wi 30-year up 11 bps to 3.67%. Wall Street was choppy as it assessed whether the report was good news on the economy, or bad news as it supported the higher for longer Fed rate stance. It was ultimately deemed "bad news" and the surge in rates exacerbated the selloff. The NASDAQ closed with a 1.59% loss, though had been down over 2% early on. The S&P 500 fell -1.04%, and the Dow slumped -0.38%. The DXY rallied and extended gains into the close, rising 2-handles to 103.006 from a low of 101.546 before finishing at 102.965. Implied Fed funds futures settled with 5% rate in June and July, though still showing rate cuts by year end.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Vapotherm files $200M mixed securities shelf  16:39
02/03/23
02/03
16:39
02/03/23
16:39
VAPO

Vapotherm

$1.07 /

+ (+0.00%)

 
ShowHide Related Items >><<
VAPO Vapotherm
$1.07 /

+ (+0.00%)

VAPO Vapotherm
$1.07 /

+ (+0.00%)

11/03/22 Piper Sandler
Vapotherm price target lowered to $1 from $2 at Piper Sandler
10/03/22 Piper Sandler
Vapotherm's latest debt amendment 'more consequential', says Piper Sandler
08/04/22 BTIG
Vapotherm downgraded to Neutral from Buy at BTIG
08/04/22 William Blair
Vapotherm downgraded to Market Perform from Outperform at William Blair
VAPO Vapotherm
$1.07 /

+ (+0.00%)

VAPO Vapotherm
$1.07 /

+ (+0.00%)

Hot Stocks
RH says certain financial statements 'should no longer be relied upon' » 16:39
02/03/23
02/03
16:39
02/03/23
16:39
RH

RH

$343.41 /

-3.65 (-1.05%)

In a regulatory filing,…

In a regulatory filing, the company said, "During the preparation of our response to a comment letter from the Division of Corporation Finance of the SEC related to a routine review of our Annual Report on Form 10-K for the fiscal year ended January 29, 2022, and Quarterly Report on Form 10-Q for the fiscal quarter ended October 29, 2022, RH became aware of errors in the calculation of net income per share. On February 1, 2023, the Audit Committee of the Board of Directors, after discussion with our senior leadership and independent registered public accountants, determined that our previously unaudited financial statements for the three months ended April 30, 2022, the three and six months ended July 30, 2022, and the three and nine months October 29, 2022 should no longer be relied upon due to material unintentional errors in certain of these financial periods with respect to our calculation of basic and diluted net income per share. Accordingly, a restatement is required to correct these errors and our Prior Financial Statements for each of the quarterly periods ended April 30, 2022, July 30, 2022, and October 29, 2022 included in the associated Form 10-Qs previously filed with the SEC should no longer be relied upon. The unintentional errors in the Prior Financial Statements were as follows: We misinterpreted relevant authoritative guidance and added back the pre-tax loss on extinguishment of debt in connection with a portion of the convertible senior notes in the computation of net income available to common stockholders used in calculating basic net income per share. As a consequence of the above errors, the computation of diluted net income per share was therefore incorrect as a result of the anti-dilutive impact of (i) adding back the pre-tax loss on extinguishment of debt and (ii) including the potential shares related to the extinguished convertible senior notes in the calculation of weighted-average diluted shares. The miscalculation of diluted net income per share became evident when correcting for the errors to basic net income per share. We will file amendments to our Quarterly Reports on Form 10-Q for the fiscal quarters ended April 30, 2022, July 30, 2022, and October 29, 2022 to correct these errors. Similarly, basic and diluted net income per share and related financial information affected by the restatement that is included in any previously issued or filed reports, press releases, earnings releases, shareholder letters, and investor presentations or other communications covering the Non-Reliance Periods should no longer be relied upon."

ShowHide Related Items >><<
RH RH
$343.41 /

-3.65 (-1.05%)

RH RH
$343.41 /

-3.65 (-1.05%)

01/11/23 BofA
Arhaus price target raised to $16.50 from $12 at BofA
01/04/23 Guggenheim
RH filing implies $400M of shares bought back in Q4-to-date, says Guggenheim
12/13/22 Needham
Williams-Sonoma initiated with a Hold at Needham
12/12/22 Cowen
RH price target lowered to $320 from $350 at Cowen
RH RH
$343.41 /

-3.65 (-1.05%)

RH RH
$343.41 /

-3.65 (-1.05%)

RH RH
$343.41 /

-3.65 (-1.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.